Journal · Updated 2026-08-11

Minnesota Medicaid and GLP-1s in 2026: Covered With Prior Authorization — and a Live Bill That Tried to End It

By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify

The coverage as it stands

Medical Assistance covers the obesity-indicated GLP-1s with prior authorization, in line with the covering-state pattern: documented BMI meeting the program's threshold, comorbidity records where required, evidence of lifestyle-intervention attempts, and prescriber persistence through the review — the prior-authorization guide's checklist applies wholesale. Most Minnesota enrollees receive drug benefits through managed-care organizations, which adds a plan-level formulary and PA layer on top of the state's; the plan's pharmacy line, not a website's summary, is the final word on which form and which documentation. One caution from our source review: at least one clinic directory circulates a specific monthly-copay figure for Minnesota's program that we could not trace to any state document — Medicaid cost-sharing runs to a few dollars per prescription, and we do not repeat the claim. That is what the evidentiary-status system is for.

The bill, the hearing, and the delay

The challenge came as a bill by Representative Danny Nadeau of Rogers to bar Medical Assistance from covering GLP-1s when used exclusively for weight loss. The cost pressure behind it is not invented: by April 2025 the average annual cost of GLP-1 treatment ran near twelve thousand dollars per person, the drugs accounted for more than twelve percent of Minnesota's pharmaceutical costs, and the state's pharmacy spending had grown by roughly a quarter in a single year. At the March 25 committee hearing, physicians, obesity-medicine specialists, and the American Diabetes Association testified against the prohibition, arguing the long-run economics of treating obesity cut the other way. Legislators delayed action — the bill was neither passed nor formally defeated as of the late-March reporting this page relies on. A delayed bill is a live bill; Minnesota enrollees planning around this coverage should treat the next legislative session as a scheduled event, not background noise.

If the door ever closes: what survives by federal rule

Should Minnesota ever join the states that ended weight-loss coverage, the pattern from California, Pennsylvania, and New Hampshire is instructive about what remains: the diabetes door for members with a type 2 diagnosis, and the non-weight indication doors — cardiovascular risk reduction, obstructive sleep apnea, chronic kidney disease, MASH — which federal rebate-program rules generally require states to cover with prior authorization because they sit outside the weight-loss exclusion, all mapped in the indication-door playbook. The under-21 EPSDT path continues everywhere. And the cash-pay floor — compounded semaglutide near one hundred dollars a month, tirzepatide under one hundred seventy on current promotional cards — is the fallback that carries the standing verification homework. The Medicaid hub and the 2026 change ledger hold the national record this page plugs into.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.